Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Breast Neoplasms, Male, Thyroid Carcinoma, Anaplastic

NCT02396368 2015-11-20

Radium-223

Phase 1 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT00006126 2015-11-13

Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery

Phase 1 Withdrawn

BreastDermatologicGenitourinaryThoracic

Testicular Germ Cell Tumor, Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Testicular Neoplasms, Small Cell Lung Carcinoma

NCT01320787 2014-10-23

18-F-Fluoroacetate as PET Imaging Agent

Phase 1 Withdrawn

BreastCNSGenitourinary

Brain Neoplasms, Breast Neoplasms, Prostatic Neoplasms, Central Nervous System Neoplasms

NCT00014287 2013-12-19

Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer

Phase 1 Withdrawn

Genitourinary

Urinary Bladder Neoplasms

NCT00110526 2013-10-24

Gene Therapy for Prostate Cancer That Returns After Radiation Therapy

Phase 1 Withdrawn

Genitourinary

Neoplasm Recurrence, Local, Prostatic Neoplasms

NCT01197209 2013-08-23

Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer

Phase 1 Withdrawn

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00005827 2012-04-24

Genistein in Treating Patients With Stage II, Stage III, or Stage IV Prostate Cancer

Phase 1 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT01441388 2011-12-20

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

Phase 1 Withdrawn

CNSGastrointestinalGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular

Clinical Trials

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer

Study of OB-002 in Patients With Refractory Metastatic Cancer

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

TRACK

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers

Investigating the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) on the Treatment of Subjects With CRPC

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Vaccine Response With NT-I7

ACTION

sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

(BLASST)-3

BrUOGPR255

Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone

Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas

PROSTIRNA

A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

Phase I Trial of PACE for Metastatic Prostate Cancer

Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma

TRIO Bladder

Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection

Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer

LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel

PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer

PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.

Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients

Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

Radium-223

Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery

18-F-Fluoroacetate as PET Imaging Agent

Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer

Gene Therapy for Prostate Cancer That Returns After Radiation Therapy

Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer

Genistein in Treating Patients With Stage II, Stage III, or Stage IV Prostate Cancer

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.